Position in DNLI
as of Jun 30, 2026
· filed Aug 19, 2026
Position Value
$418,130
-$187,798 QoQ
Shares Held
16,257
-38.2% QoQ
Ownership
0.010%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#159
of 290 holders
Holding Since
Sep 2021
8 quarters on record
Voting authority
Sole 16%
Shared 0%
None 84%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MERCER GLOBAL ADVISORS INC /ADV holds $302,411,362 across 140 Biotechnology names. DNLI ranks #50 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APGE |
Apogee Therapeutics, Inc.
|
941,283 | $124,936,492 | |
| 2 | CAPR |
Capricor Therapeutics, Inc.
|
802,732 | $19,329,786 | |
| 3 | ORMP |
Oramed Pharmaceuticals Inc.
|
3,810,540 | $18,328,697 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
30,705 | $15,252,094 | |
| 5 | INCY |
Incyte Corp
|
116,207 | $13,173,225 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
20,126 | $12,549,366 | |
| 7 | EXEL |
Exelixis, Inc.
|
176,339 | $9,594,604 | |
| 8 | CORT |
Corcept Therapeutics Inc
|
102,823 | $8,940,459 |
All Filings in DNLI
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $418,130 | 16,257 | Shares | Sole | 2026-08-19 | |
| 2023-03-31 | $605,928 | 26,299 | Shares | Sole | 2023-05-16 | |
| 2022-12-31 | $751,704 | 27,030 | Shares | Sole | 2023-02-09 | |
| 2022-09-30 | $804,354 | 26,209 | Shares | Sole | 2022-11-15 | |
| 2022-06-30 | $702,288 | 23,863 | Shares | Sole | 2022-08-10 | |
| 2022-03-31 | $737,175 | 22,915 | Shares | Sole | 2022-05-10 | |
| 2021-12-31 | $773,899 | 17,352 | Shares | Sole | 2022-02-04 | |
| 2021-09-30 | $985,439 | 19,533 | Shares | Sole | 2021-11-10 | |
| No filing history on record for this holder in this stock. | ||||||